Roche Buy Anadys Pharmaceuticals for $230 Million

Swiss pharmaceutical company, Roche, is to acquire the USA’s Anadys Pharmaceuticals, a hepatitis C specialist, in a cash agreement worth about $230 million. The Swiss company is paying $3.70 per share cash, which represents a 256% premium over Anadys’ closing price of $1.04 on Friday (October 14). The San Diego-based group’s board have agreed to

Continue Reading